Motesanib reduced VEGF-stimulated HUVEC proliferation over four days at 5–25 nM. At 25 nM without added VEGF, no significant antiproliferative effect was reported. [1]
In a 72-hour proliferation assay, motesanib had an IC50 of 10 nM in VEGF-stimulated HUVECs and >5,000 nM in each of five NSCLC cell lines. These findings indicate a strong dependence on cellular context. [2]
VEGFR2 kinase activity
Biochemical assay · VEGFR2 kinase activity measured with the HTScan VEGF Receptor 2 Kinase Assay Kit [1]
Motesanib reduced VEGFR2 kinase activity across serial dilutions. The study supports VEGFR2 inhibition without establishing a numerical IC50 in this record.
Literature-Reported Treatment Conditions
- Treatment concentration
- Serial dilutions of motesanib (Figure 1B)
- Method
- In vitro VEGFR2 kinase assay according to kit instructions
- Reported limits
- Main text does not specify assay incubation time, ATP concentration, replicate number or vehicle for this kinase assay; these are not borrowed from cellular experiments.
Methods and source locations
Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified
Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.
Materials and Methods: VEGFR kinase assay; Results: Motesanib has specific activity on HUVECs in vitro; Figure 1B and caption
VEGFR2 kinase activity: HTScan VEGF Receptor 2 Kinase Assay Kit; activity plotted as percent kinase activity. No IC50 estimated from the curve. — Figure 1B; Materials and Methods: VEGFR kinase assay
VEGF-dependent HUVEC proliferation
Cell-based study · Human umbilical vein endothelial cells in EBM-2 basal medium with 2% FBS and no added growth supplements [1]
Motesanib inhibited VEGF-stimulated proliferation in a concentration-dependent manner. At 25 nM without added VEGF, no significant antiproliferative effect was reported.
Literature-Reported Treatment Conditions
- Treatment concentration
- Motesanib 5, 10 and 25 nM with VEGF; 25 nM in the no-added-VEGF control
- Exposure duration
- 4 days
- Method
- VEGF stimulation: 25 ng/mL every 24 hours; crystal violet proliferation assay
- Vehicle
- 0.25% DMSO in all wells
- Co-treatment
- VEGF stimulation, not an anticancer-drug combination
- Reported limits
- Six wells per condition are reported; number of independent biological repeats is not specified in the retrieved assay description.
Methods and source locations
Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified
Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.
Materials and Methods: HUVEC proliferation assays, Crystal violet assay; Results: Motesanib has specific activity on HUVECs in vitro; Figure 1A and caption
VEGF-stimulated HUVEC proliferation: Crystal violet staining intensity after 4 days; VEGF 25 ng/mL every 24 hours. No numerical IC50 reported for this assay. — Figure 1A and caption; Materials and Methods: Crystal violet assay
HUVEC proliferation without added VEGF: Basal medium comparison with vehicle and 25 nM motesanib, without added VEGF. — Figure 1A; Results: Motesanib has specific activity on HUVECs in vitro
Endothelial versus NSCLC proliferation response
Cell-based study · HUVECs stimulated with VEGF; A549, Calu-6, NCI-H358, NCI-H1650 and NCI-H1299 NSCLC cells [2]
Motesanib had a reported proliferation IC50 of 10 nM in VEGF-stimulated HUVECs and >5000 nM in each of five NSCLC cell lines. Docetaxel inhibited all tested cell lines, providing a pharmacological comparator.
Literature-Reported Treatment Conditions
- Treatment concentration
- Motesanib 0.0025–5000 nM; separate comparator docetaxel 0.001–5000 nM (10-point serial dilutions)
- Exposure duration
- 72 hours after overnight plating
- Method
- NSCLC cells in DMEM high glucose with 10% FBS and 2 mM L-glutamine; HUVEC motesanib assay in DMEM high glucose with 2 mM L-glutamine and 50 ng/mL recombinant human VEGF
- Vehicle
- Motesanib in medium containing 1% DMSO; docetaxel in PBS
- Co-treatment
- None in the adopted single-agent panel; docetaxel is a separate comparator
- Reported limits
- Duplicate treatments are reported; independent biological repeat count is not specified. The figure curve/control labels include PBS and 0 nM motesanib; a separate DMSO-only curve is not identified.
Methods and source locations
Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified
Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.
Methods: In vitro cell proliferation assays; Results: Expression of VEGFR2 and effect of motesanib on NSCLC tumor cell proliferation; Figure 1B–C and caption
VEGF-stimulated HUVEC proliferation: ATPlite 1-step luminescence viability assay after 72 hours; treatments in duplicate. — Figure 1B–C; Methods: In vitro cell proliferation assays
Proliferation of A549, Calu-6, NCI-H358, NCI-H1650 and NCI-H1299: ATPlite 1-step luminescence viability assay after 72 hours; treatments in duplicate. — Figure 1B–C; Methods: In vitro cell proliferation assays
Docetaxel comparator proliferation response: Same cell panel and 72-hour viability assay; docetaxel tested separately from motesanib. — Figure 1B; Methods: In vitro cell proliferation assays